Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 120 companies set new 52-week lows.
Fighting Omicron: This Covid Vaccine Candidate Is Going After The Dangerous Mutation
CureVac N.V. (NASDAQ:CVAC) and GSK plc (NYSE:GSK) have started a Phase 1 trial of the modified COVID-19 mRNA vaccine candidate, administered as a…
Stocks That Hit 52-Week Lows On Thursday
During Thursday's trading, 62 companies set new 52-week lows.
AstraZeneca Slaps Lawsuit Against Former Employee As He Moves To Close Rival: Report
AstraZeneca Plc (NASDAQ:AZN) has filed suit against former VP and head of investor relations Chris Sheldon as he prepares…
GSK’s Rare Blood Cancer Candidate Goes Under FDA Review
The FDA has accepted GSK plc’s (NYSE:GSK) marketing application for momelotinib, a potential new medicine with a proposed differentiated mechanism of…
GSK Announced FDA Accepted New Drug Application for Momelotinib for the Treatment of Myelofibrosis
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for momelotinib, a potential new medicine with a proposed differentiated mechanism of action that may address the significant unmet medical needs of myelofibrosis patients with anaemia. The US FDA has assigned a Prescription Drug User Fee Act action date of 16 June 2023.
‘Statement: Zantac (ranitidine) U.S. litigation | GSK’ – gsk.com
https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-us-litigation/
Why IDEAYA Biosciences Shares Plunging Today
Earlier today, IDEAYA Biosciences Inc (NASDAQ:IDYA) reported Q2 results, and shares have plunged 30% after the update. Investors are probably reacting…
